231 patients suffering from Alzheimer's disease were recruited to participate in this study to determine the preventative effects of menatetrenone, risedronate and calcium on hip fractures, over one year. All patients were administered 17.5 mg risedronate and 1200mg calcium weekly; patients were then randomized to receive 45mg menatrenone daily or a placebo. The results suggested that menatetrenone, risedronate and calcium were a safe combination of medications that prevented fractures and increased bone mineral density in elderly patients with Alzheimer’s.